Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 37Gastrointestinal 20Dermatologic 17Thoracic 12Gynecologic 9Genitourinary 9Breast 4Other solid neoplasm 2Lymphoid 2Sarcoma 1Other 1NET 1Endocrine 1

Conditions

Lymphoma 2981Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Lymphoma, Non-Hodgkin 2265Leukemia, Lymphocytic, Chronic, B-Cell 1992Lymphoma, Follicular 1847Lymphoma, Large B-Cell, Diffuse 1784Leukemia 1339Hodgkin Disease 1292Lymphoma, Mantle-Cell 1193Leukemia, Myeloid, Acute 978Burkitt Lymphoma 955Multiple Myeloma 866Lymphoma, B-Cell, Marginal Zone 853Recurrence 839Lymphoma, B-Cell 754Myelodysplastic Syndromes 682Neoplasms 593Lymphoma, T-Cell, Cutaneous 543Waldenstrom Macroglobulinemia 514Lymphoma, Large-Cell, Immunoblastic 490Mycosis Fungoides 438Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Lymphoma, Large-Cell, Anaplastic 390Sezary Syndrome 364Lymphoma, T-Cell, Peripheral 350Hematologic Neoplasms 350Leukemia, Myelogenous, Chronic, BCR-ABL Positive 334Myeloproliferative Disorders 328Neoplasms, Plasma Cell 309Blast Crisis 284

Interventions

pembrolizumab 2durvalumab 1atezolizumab 1advexin 1Nivolumab 1Injections, Subcutaneous 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Lymphoid × Clear all
NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

Phase 1 Terminated
159 enrolled
DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡